LKT Labs

Biochemicals for Life Science Research

Acalabrutinib

Acalabrutinib

Product ID A081014
Cas No. 1420477-60-6
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $116.00 In stock
25 mg $307.00 In stock
100 mg $886.00 In stock
Bulk Quote

Quicklinks

Description

Acalabrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It showed increased selectivity compared with first generation BTK inhibitors such as ibrutinib while offering similar antitumor efficacy in mouse models of chronic lymphocytic leukemia. It has been approved for the treatment of patients with relapsed mantle cell lymphoma(MCL), a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. It is currently being investigated as a front line treatment for MCL.

Product Info

Cas No.

1420477-60-6
Purity

≥99%
Formula

C26H23N7O2
Formula Wt.

465.52
IUPAC Name

4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide
Synonym

ACP-196

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

A081014 MSDS PDF
Info Sheet

A081014 Info Sheet PDF

References

Herman S., Montraveta A., et al. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clin Cancer Res. 23(11):2831-41 (2016). PMID:27903679.

Witzig T., Inwards D. Acalabrutinib for mantle cell lymphoma. Blood. 133(24):2570-74 (2019). PMID: 30967367.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • N4524

    NLG919

    Indoleamine-2,3-dioxygenase inhibitor.

    ≥98%
  • A0816

    Acemetacin

    Glycolic acid ester prodrug of indomethacin, NS...

    ≥98%
  • R2713

    Recombinant HCV-NS4 Antigens

    Recombinant HCV antigen fragment.

    ≥95%
  • C1621

    CEF4

    Peptide, vSrc-induced cytokine.

    ≥95%
  • G1408

    GDC-0449

    Smo inhibitor.

    ≥98%
  • F4420

    Boc-FLFLF

    Peptide; FRP1 antagonist.

    ≥95%
  • A2048

    Aflatoxin G1

    Mycotoxin produced by species of Aspergillus; D...

    ≥98%
  • P1849

    Pemetrexed Disodium

    Thymidylate synthase inhibitor, potential SHMT,...

    ≥98%
  • B030964

    BAY-1816032

    BUB1 inhibitor.

    ≥99%
  • C0250

    Calcitonin Gene Related Peptide II, human

    Calcitonin-family peptide, involved in vasodila...

    ≥95%
  • D0033

    Daidzin

    Isoflavone, phytoestrogen, found in soy.

    ≥98%
  • D3304

    Dibenzoylmethane, 98%

    Aromatic 1,3-diketone acetylacetone derivative ...

    ≥98%
  • A0910

    N-Acetyl-S-(N′-phenylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant.

    ≥98%
  • D3210

    Diclofenac free acid

    Somewhat selective in inhibiting COX-2 over COX...

    ≥99%
  • G0250

    cGAMP Disodium [STING Ligand]

    Cyclic dinucleotide that detects cytosolic DNA ...

    ≥98%
  • S0344

    Salermide

    SIRT inhibitor.

    ≥98%
  • S3346

    Silodosin

    α1A-adrenergic antagonist.

    ≥98%
  • C2468

    β-Calcitonin Gene Related Peptide, human

    Endogenous calcitonin-family peptide, involved ...

    ≥98%
  • E6256

    Epothilone A

    Microtubule depolymerization inhibitor.

    ≥95%
  • L1616

    LEE-011

    CDK4/6 inhibitor.

    ≥98%